Newsmakers: Vigene Biosciences Dr. Jeffrey Hung, Chief Commercial Officer, discusses Vigene’s new $20 million lab and strategic partnership with ASC Therapeutics

Contract Pharma talks with Dr. Jeffrey Hung, Chief Commercial Officer of Vigene Biosciences, about the strategic partnership, supporting manufacturing, and the future of cell and gene therapies. Please click here to view more.